Roche extends China deal streak with $1B pact for RNAi obesity drug
BioPharma Dive reports that Roche signed a licensing deal with China-based Rona Therapeutics, paying $100 million for full ownership of an experimental RNA interference drug aimed at ALK7, a receptor frequently expressed in fat tissue, with total payments potentially just over $1 billion. Several companies are pursuing ALK7 to lower visceral fat, though the outlet notes research remains early.
Why it matters: Relevant to Maryland adults exploring medical weight loss and the clinicians who refer them, especially those following early-stage obesity drugs beyond current incretin medicines.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to biopharmadive.com. October 13, 2026.
